Agios Pharmaceuticals announced it will stop developing tebapivat, a drug for sickle cell disease, after Phase 2 trial results failed to meet expectations. Following this news, the company's stock price fell 6.74%. Pomerantz LLP is investigating whether Agios and its executives engaged in securities fraud or unlawful business practices related to this announcement. Investors affected by this situation are encouraged to contact the law firm for potential class action participation.
HIVE Digital Technologies, through its subsidiary BUZZ High Performance Computing, signed a $350 million five-year GPU cloud services contract with an investment-grade customer. This deal adds about $70 million in annual revenue, raising BUZZ HPC's t...
Gunnison Copper Corp. has completed the initial metallurgical drilling phase at its Gunnison deposit and started similar work at the Strong & Harris deposit in Arizona. The company is conducting extensive metallurgical tests, including flotation and ...
Centene announced that CFO Drew Asher will step down in December 2026 and retire by the end of 2027. Chris Neczypor, with extensive finance and strategy experience, will join Centene in September and take over as CFO on January 1, 2027. Asher will re...
Dingdong (Cayman) Limited, a leading fresh grocery e-commerce company in China, announced it will report its unaudited financial results for the second quarter ending June 30, 2026, on August 20 before the US markets open. The company is known for it...
China Automotive Systems, Inc. announced that its subsidiary Jingzhou Henglong Automotive Parts Manufacturing has been recognized as a national-level Green Factory for 2025 by China's Ministry of Industry and Information Technology. This marks the co...
